What is CLCS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CLCS?

P/E (TTM) is n/a and 52-week range is $0.25 to $2.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CLCS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CLCS?

The company profile lists net income (TTM) near $-7M, EPS (TTM) near $-0.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cell Source Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 68M shares outstanding, ISIN US15114L1044 when available from company profile and filing metadata.

Cell Source Inc

$CLCS

Health Care · Biotechnology

IR Run Scenarios

$0.55

+9.32%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. The company is headquartered in New York City, New York. The company went IPO on 2014-01-14. The firm is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The firm's wholly owned subsidiary is Cell Source Limited (CSL).

Website

cell-source.com/

IPO

2014-01-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)